Author

E. Atkins

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:E. coli· 1 Organism:virus· 1

Frequent Co-Authors

A. Dell· 1 shared B. Lehri· 1 shared B. W. Wren· 1 shared C. S. McKimmie· 1 shared C. Scott· 1 shared D. Goldhill· 1 shared E. Bakke· 1 shared E. Kay· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Dell

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development of a novel glycoengineering platform for the rapid production of conjugate vaccines.

S. Abouelhadid, E. Atkins, E. Kay, I. Passmore, S. J. North, B. Lehri, P. Hitchen, E. Bakke, M. Rahman, J. Bosse, Y. Li, V. S. Terra, P. Langford, A. Dell, B. W. Wren, J. Cuccui

This paper develops a novel glycoengineering platform, MAGIC, which increases glycoconjugate yield and enables vaccine development in genetically intractable bacteria.

bioRxiv · Nov 25, 2021Microbiology

Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza

C. Scott, J. Kankanala, T. L. Foster, D. Goldhill, K. J. Simmons, M. Pingen, M. J. Bentham, E. Atkins, E.-A. Loundras, R. Elderfield, J. K. Claridge, J. Thompson, R. Stilwell, R. Tathineni, C. S. McKimmie, , S. Griffin

The paper identifies M2-N31 inhibitors that show synergistic antiviral effects when combined with existing drugs, offering a strategy to combat rimantadine-resistant influenza.

bioRxiv · Jul 24, 2019Microbiology